Skip Ribbon Commands
Skip to main content
CIBMTR

COVID-19 Updates

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   /   COVID-19 Updates
  • Print
  • Share

 COVID-19 Updates

Reported Data
Data Collection
Published Study Results
Ongoing Studies
Communications
Additional Resources


COVID-19 Reported Data

As of 8/13/20

Number of COVID-19 Infections: 418

Number of Centers Reporting: 110 (92 US, 18 non-US)

 


SEE DATA BREAKDOWNS BY:

  • Patient sex
  • Type of cellular therapy
  • Age at infection
  • US region
  • Time from infusion

Data Collection

Quick Links:

The CIBMTR continues to collect data and reimburse centers. FormsNet3 and CIBMTR Center Support are fully operational.

New Form: Respiratory Virus Post-Infusion Data Form (2149)

  • Now available in FormsNet3.
  • Collects detailed data regarding the diagnosis, treatment, and outcomes of COVID-19 infections.
  • Centers will be reimbursed for completing this form.
  • Reinfection: If a patient tests positive again >21 days after resolution, please report a new COVID-19 infection.
  • More information: 4/1/204/10/204/21/20, 5/11/20, 7/14/20

New COVID-19 Diagnosis on Data Collection Forms

  • COVID-19 diagnosis can now be reported on the F2100 and F4100. More information: 3/26/20
  • F2400, F4000, F2450, and F2900 now include questions related to COVID-19 infections. More information: 4/10/20, 5/11/20

Continue to Consent Patients to the Research Database

  • Consent can be obtained by the clinician consenting the patient to HCT or other cellular therapy.
  • No evaluations or appointments are required that are not standard of care.
  • There is no additional risk to patients, clinicians, or study staff.
  • Position statement from the CIBMTR and ASTCT, urging continued consent and enrollment of patients in the CIBMTR's Database Protocol.

Prioritize Data Collection for:

  • Respiratory Virus Post-Infusion Data Form (2149)
  • Consecutive Transplant Audit
  • Recipients on studies, especially BMT CTN
  • More information: 3/20/20, 4/10/20, 5/1/20

CPI, Data Audits, and One Year Forms Due Requirement for Reimbursement

  • Continuous process improvement (CPI) requirements are reinstated for the trimester ending 12/31/20 for all product types via a "ramp up" plan. More information: 3/16/20, 5/1/20, 8/11/20
  • On-site CIBMTR data audits are evaluated 8 weeks prior to the scheduled date. If the on-site audit cannot be conducted, audits may be conducted remotely or rescheduled for a later date. More information: 3/20/20, 5/1/20
  • Requirement that forms be submitted within one year of their due date in order to be reimbursed is suspended for forms due 3/1/20 or later. More information: 4/1/20

COVID-19 Published Study Results

Frigault MJ, Nikiforow S, Mansour M, et al. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19? Blood. 2020 May 26. doi.org/10.1182/blood.20200062. [Epub ahead of print]

Eapen M, Zhang MJ, Tang XY, et al. Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia. Biology of Blood and Marrow Transplantation. 2020 May 8. doi:10.1016/j.bbmt.2020.04.027. [Epub ahead of print]

Hamadani M, Zhang M-J, Tang X-Y, et al. Graft cryopreservation does not impact overall survival after allogeneic HCT using post-transplant cyclophosphamide for GVHD prophylaxis. Biology of Blood and Marrow Transplantation. 2020 Apr 10.
doi:10.1016/j.bbmt.2020.04.001. [Epub ahead of print]

  • Conclusion: Graft cryopreservation does not significantly delay hematopoietic recovery, increase acute GVHD risk or non-relapse mortality, or decrease overall survival after allogeneic HCT using posttransplant cyclophosphamide.
  • Plain language summary: Freezing cells for blood and marrow transplant saves lives


Ongoing Studies

Working Committee Studies Continue

  • If you are a study PI, let your statistician know if you are unable to maintain your previous study timeline.
  • Studies requiring supplemental data collection will likely be delayed.
  • More information: 3/27/20

RCI BMT and BMT CTN Trials Affected

  • Accrual is temporarily suspended for some trials, and accrual is restricted for others.
  • On-site monitoring is suspended.
  • More information: BMT CTN SharePoint website (password required)

Communications

COVID-19
​August 11, 2020
​Reinstating CPI (PDF)
​July 14, 2020
Reporting COVID-19 Reinfection (PDF)
​June 23, 2020
​Reporting Cause of Death for Recipients with COVID-19 (PDF)
​May 11, 2020Respiratory Virus Post-Infusion Form (2149) Released in FormsNet3; Additional Form Modifications (PDF)
​May 1, 2020

​Continuous Process Improvement (CPI), Consecutive Transplant Audit (CTA), and Clinical Data Validation (Audit) (PDF)

​April 21, 2020

​Updates to the Fillable PDF Respiratory Virus Post-Infusion Form (2149) (PDF)

​April 15, 2020

Email to Medical Directors: 
Continuing to Register Patients with CIBMTR (PDF)

Position Statement: Reporting to the CIBMTR during the COVID-19 Pandemic (PDF)

​April 10, 2020

​Form 2149 FAQ, FormsNet Spring Released Delayed & Reporting Priorities (PDF)

​April 1, 2020

Reimbursement for Forms Submitted One Year After Due Date & Respiratory Virus Post-Infusion Form (2149) (PDF)

​March 27, 2020

Working Committees and the CIBMTR

March 26, 2020

​Collecting Data on the Impact of the COVID-19 Pandemic on our Transplant and Cell Therapy Recipients (PDF)

​March 24, 2020

​COVID-19 Impact to CIBMTR International Centers (PDF) 

​March 20, 2020

​COVID-19 Impact to CIBMTR Network Centers in the US (PDF)

​March 16, 2020

COVID-19 and CPI Standards (PDF)


Additional Resources

ASTCT's COVID-19 Resource Community

Be The Match's COVID-19 FAQs




Last Updated: 8/13/2020 8:50 AM
CIBMTR